Darío Rubio-Rodríguez1, Silvia De Diego Blanco2, Maite Pérez3, Carlos Rubio-Terrés4. 1. Health Value, C/Virgen de Aránzazu, 21, 5° B, 28034, Madrid, Spain. 2. Market Access Department, Astellas Pharma, SA, Madrid, Spain. 3. Medical Department, AstraZeneca Farmacéutica Spain, Barcelona, Spain. 4. Health Value, C/Virgen de Aránzazu, 21, 5° B, 28034, Madrid, Spain. drubiorodriguez@healthvalue.org.
Abstract
BACKGROUND: Until recently, advanced melanoma (unresectable and metastatic) has had a poor prognosis and has been treated with chemotherapy. The introduction of new treatments (BRAF and MEK inhibitors and immunotherapy) has improved overall survival and progression-free survival of some patients. OBJECTIVE: The objective of this study was to review the published evidence on the cost-effectiveness of pharmacological treatments for advanced melanoma. METHODS: A systematic literature search was conducted, without date or language restrictions, in PubMed, EMBASE, Scopus, the Cochrane Library, the UK National Institute for Health and Care Excellence databases and the Health Technology Assessment journal. Internet searches were also made to identify possible grey literature. Main study characteristics, methods and outcomes were extracted and critically assessed. The quality of health economic studies was assessed by the Quality Assessment of Economic Evaluation in Health Care checklist. RESULTS: The search identified nine full-text pharmacoeconomic analyses of advanced melanoma treatments. According to the economic analyses published in the articles, the new treatments have been shown to be more effective (with more life-years and quality-adjusted life-years) than chemotherapy, although generally the cost per quality-adjusted life-year gained was above the commonly accepted threshold. Because of the variability of the available analyses comparing the new treatments, we cannot determine which treatment is the most cost-effective. CONCLUSIONS: From the available data, it cannot be concluded that the new drugs (BRAF and MEK inhibitors and immunotherapy) are cost effective compared with chemotherapy or which is the most cost-effective new treatment.
BACKGROUND: Until recently, advanced melanoma (unresectable and metastatic) has had a poor prognosis and has been treated with chemotherapy. The introduction of new treatments (BRAF and MEK inhibitors and immunotherapy) has improved overall survival and progression-free survival of some patients. OBJECTIVE: The objective of this study was to review the published evidence on the cost-effectiveness of pharmacological treatments for advanced melanoma. METHODS: A systematic literature search was conducted, without date or language restrictions, in PubMed, EMBASE, Scopus, the Cochrane Library, the UK National Institute for Health and Care Excellence databases and the Health Technology Assessment journal. Internet searches were also made to identify possible grey literature. Main study characteristics, methods and outcomes were extracted and critically assessed. The quality of health economic studies was assessed by the Quality Assessment of Economic Evaluation in Health Care checklist. RESULTS: The search identified nine full-text pharmacoeconomic analyses of advanced melanoma treatments. According to the economic analyses published in the articles, the new treatments have been shown to be more effective (with more life-years and quality-adjusted life-years) than chemotherapy, although generally the cost per quality-adjusted life-year gained was above the commonly accepted threshold. Because of the variability of the available analyses comparing the new treatments, we cannot determine which treatment is the most cost-effective. CONCLUSIONS: From the available data, it cannot be concluded that the new drugs (BRAF and MEK inhibitors and immunotherapy) are cost effective compared with chemotherapy or which is the most cost-effective new treatment.
Authors: K Matter-Walstra; R Braun; C Kolb; Z Ademi; R Dummer; B C Pestalozzi; M Schwenkglenks Journal: Br J Dermatol Date: 2016-01-20 Impact factor: 9.302
Authors: Esther Bastiaannet; Carin A Uyl-de Groot; Adrienne H Brouwers; Eric J van der Jagt; Otto S Hoekstra; Wim Oyen; Fred Verzijlbergen; Bart van Ooijen; John F Thompson; Harald J Hoekstra Journal: Ann Surg Date: 2012-04 Impact factor: 12.969
Authors: Megan A Bohensky; Kumar Pasupathi; Alexandra Gorelik; Hansoo Kim; James P Harrison; Danny Liew Journal: Value Health Date: 2016-12 Impact factor: 5.725
Authors: Janice N Cormier; Yan Xing; Meichun Ding; Scott B Cantor; Kristi J Salter; Jeffrey E Lee; Paul F Mansfield; Jeffrey E Gershenwald; Merrick I Ross Journal: J Clin Oncol Date: 2007-06-10 Impact factor: 44.544
Authors: D Lee; A Amadi; J Sabater; J Ellis; H Johnson; S Kotapati; S McNamara; A Walker; M Cooper; K Patterson; N Roskell; Y Meng Journal: Pharmacoecon Open Date: 2019-03
Authors: Hae-Young Park; Jinseub Hwang; Do-Hyang Kim; Soo Min Jeon; Sun Ha Choi; Jin-Won Kwon Journal: BMC Cancer Date: 2020-09-03 Impact factor: 4.430
Authors: Amr Makady; Ard van Veelen; Páll Jonsson; Owen Moseley; Anne D'Andon; Anthonius de Boer; Hans Hillege; Olaf Klungel; Wim Goettsch Journal: Pharmacoeconomics Date: 2018-03 Impact factor: 4.981